华恒生物
(688639)
| 流通市值：71.82亿 | | | 总市值：71.82亿 |
| 流通股本：2.50亿 | | | 总股本：2.50亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 687,062,042.25 | 2,177,940,839.23 | 1,539,034,126.35 | 1,016,220,737.71 |
| 营业收入 | 687,062,042.25 | 2,177,940,839.23 | 1,539,034,126.35 | 1,016,220,737.71 |
| 二、营业总成本 | 632,740,817.63 | 2,017,012,228.65 | 1,382,619,720.33 | 870,509,300.9 |
| 营业成本 | 520,050,741.13 | 1,635,104,748.01 | 1,106,078,300.23 | 695,125,414.56 |
| 税金及附加 | 3,450,166.66 | 13,782,184.45 | 9,490,869.04 | 5,854,869.36 |
| 销售费用 | 20,860,067.94 | 63,591,106.64 | 46,968,066.1 | 31,571,070.71 |
| 管理费用 | 49,278,797.45 | 157,891,420.89 | 110,141,858.91 | 66,905,121.43 |
| 研发费用 | 33,876,164.43 | 124,047,025.11 | 90,514,239.06 | 63,352,200.84 |
| 财务费用 | 5,224,880.02 | 22,595,743.55 | 19,426,386.99 | 7,700,624 |
| 其中:利息费用 | 12,538,281.1 | 37,866,612 | 27,120,928.31 | 16,590,223.23 |
| 其中:利息收入 | 4,523,544.33 | 4,392,036.06 | 2,735,635.59 | 2,080,128.52 |
| 加:投资收益 | 227,967.9 | 853,142.53 | 1,043,111.4 | -51,080.29 |
| 资产处置收益 | - | -64,164.74 | -71,933.9 | -66,998.76 |
| 资产减值损失(新) | - | -3,179,964.26 | -183,649.98 | -183,649.98 |
| 信用减值损失(新) | -2,974,652.42 | 1,080,421.6 | 472,163.36 | 521,596.53 |
| 其他收益 | 3,626,474.33 | 39,698,727.78 | 24,805,207.35 | 17,482,098.66 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 55,201,014.43 | 199,316,773.49 | 182,479,304.25 | 163,413,402.97 |
| 加:营业外收入 | 183,697.63 | 3,423,968.17 | 2,361,878.04 | 1,209,998.98 |
| 减:营业外支出 | 702,109.31 | 1,335,733.12 | 730,426.76 | 129,754.15 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 54,682,602.75 | 201,405,008.54 | 184,110,755.53 | 164,493,647.8 |
| 减:所得税费用 | 5,543,643.32 | 16,847,127.96 | 16,114,036.83 | 16,501,535.83 |
| 六、净利润 | 49,138,959.43 | 184,557,880.58 | 167,996,718.7 | 147,992,111.97 |
| 持续经营净利润 | 49,138,959.43 | 184,557,880.58 | 167,996,718.7 | 147,992,111.97 |
| 归属于母公司股东的净利润 | 51,096,095.71 | 189,518,896.19 | 169,893,703.83 | 149,707,731.84 |
| 少数股东损益 | -1,957,136.28 | -4,961,015.61 | -1,896,985.13 | -1,715,619.87 |
| (一)基本每股收益 | 0.2 | 0.82 | 0.74 | 0.95 |
| (二)稀释每股收益 | 0.2 | 0.82 | 0.74 | 0.95 |
| 八、其他综合收益 | -15,972.35 | 238,507.11 | -196,251.65 | 88,915.74 |
| 归属于母公司股东的其他综合收益 | -15,972.35 | 238,507.11 | -196,251.65 | 88,915.74 |
| 九、综合收益总额 | 49,138,959.43 | 184,796,387.69 | 167,800,467.05 | 148,081,027.71 |
| 归属于母公司股东的综合收益总额 | 51,096,095.71 | 189,757,403.3 | 169,697,452.18 | 149,796,647.58 |
| 归属于少数股东的综合收益总额 | -1,957,136.28 | -4,961,015.61 | -1,896,985.13 | -1,715,619.87 |
| 公告日期 | 2025-04-23 | 2025-04-23 | 2024-10-29 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |